Last month, the FDA quietly added a proposed rule to the 2026 Unified Agenda that – if finalised – could make prescription drug advertising untenable.
Organisations must remain agile and decisive across global portfolios, anticipating regulatory changes before they create clinical trial delays.
Kim Innes is General Manager of Teva UK. She has more than 30 years’ experience across the pharmaceutical industry.
Across four days in Sweden, EHA 2026 offered a clear view of the future of blood cancer care.
Editor's Picks
